Events
SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester the launch of a pilot study it will conduct with the Mayo Clinic to evaluate and optimize its diagnostic services focused on primary cutaneous melanoma.
Summit Therapeutics plc and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with C. difficile infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC.
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain.
Flexion Therapeutics, Inc. announced its sponsorship of “Prescribed to Death: A Memorial to the Victims of the Opioid Crisis.” The national traveling exhibit is dedicated to building awareness of the continuing opioid crisis in the United States and was developed by the National Safety Council (NSC) as part of the Stop Everyday Killers public education campaign.
TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency
During the European Society of Medical Oncology (ESMO) Congress, to be held from September 27th to October 1st in Barcelona, the recent results of the lurbinectedin trial for the treatment of progressive malignant pleural mesothelioma, carried out by SAKK in collaboration with PharmaMar, will be presented.
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platforms, will present the anti-cancer impact of its TheraT® technology in four poster presentations at the CICON Cancer Immunotherapy Conference taking place September 25-28 in Paris.
Owkin announces that Dr Gilles Wainrib, Co-founder and Chief Scientific Officer at Owkin, will present at the special session on Artificial Intelligence at the European Society for Medical Oncology Congress 2019 in Barcelona, Spain on Saturday, September 28, 2019.
Herbert ‘Herb’ Heyneker, Chairman of the Board of Directors at Mimetas and Dutch biotech pioneer, has been honored by the Dutch Monarchy for his contributions and commitment to biotechnology in the Netherlands and Leiden.
Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder associated with Alzheimer’s disease/dementia will be presented at World Sleep Congress, from September 20 to 25 in Vancouver, Canada.
PRESS RELEASES